Tagged with HR

Germany The latest pharma industry news from Germany, including Lilly’s new German plant; Bayer’s aborted anti-clotting drug trial and legal worries; Boehringer Ingelheim’s acquisition of Swiss biotech T3 Pharmaceuticals, and Hermes Pharma’s plans to spend EUR 25 million euros to enhance its production capabilities.   Eli Lilly plans new 2 billion…

Morocco Dr Anthony Y. Lauw, GM & Head of Human Pharma Northwest Africa at Boehringer Ingelheim, explains the operations of a cluster that has typically worked with local partners, but that now has also opened a new scientific office in Casablanca with the idea of expanding the company’s on-ground operations in…

Hong Kong While much of PharmaBoardroom’s recent report on Hong Kong and the Greater Bay Area looks at how Hong Kong is attempting to position itself as a development and financing hub for health tech start-ups, just as important are the multinational pharma companies with commercial operations in the city, providing Hong…

UAE Thanks to favourable regulations from the Ministry of Health and Prevention (MoHaP) which include fast-track regulatory pathways, patients in the UAE are gaining access to innovative medicines in similar time frames to their counterparts in the US and Europe, in some cases even ahead. Against this backdrop, the representatives of…

UAE With cutting-edge hospital infrastructure being put in place, government authorities rolling out evermore supportive regulatory upgrades, big pharma championing ‘clinical trial diversity’ with greater non-Caucasian representation in trial cohorts, and a high regional prevalence of genetic diseases, it seems that the stage is set for the UAE to assume a…

Global Mohamed Meshref M.D, PhD is a Professor of Oncology at Cairo University and Regional Medical Director at Boehringer Ingelheim for India, Middle East, Turkey & Africa (IMETA). Here, Prof. Meshref discusses the importance of an ‘early medical affairs mindset’ within the pharma industry whereby medical affairs personnel engage much earlier…

Morocco Maphar, a 72-year mainstay of the Moroccan pharma industry with both production and distribution arms, has achieved considerable success in recent years, expanding its international network to now reach over 42 big-name partners. General Manager Pierre Labbé outlines the significant footprint of the company – part of the CFAO Group…

India A roundup of some of the top stories from the Indian pharma industry including the suspension of the National Medical Commission’s (NMC) guidelines making the prescription of generic drugs mandatory; the government’s revision of Good Manufacturing Practices (GMP) in light of deaths linked to Indian-made cough syrups; Torrent Pharma’s new…

UAE CSL Behring – which specalises in plasma-derived, and recombination therapeutic products – has undergone significant expansion in the Middle East and Africa (MEA) region in recent years under Hassan Herrou. He explains why building partnerships with the relevant authorities as well as patient associations is vital to fostering access in…

Global 2023 got off to a good start for Boehringer Ingelheim’s human pharma division. Not only has the year begun with substantial sales growth thanks to the German firm’s diabetes and heart failure drug, Jardiance, the company is also advancing on a number of other fronts. While Jardiance is expected to…

UAE PHRMAG represents the interests of the 26 leading research-driven biopharmaceutical companies in the Gulf region. Acting Secretary General Shahad Mahdi outlines the association’s core priorities, how it fosters partnerships to drive access to innovation in the region, and how significant global trends like digitalisation are playing out in Gulf pharma.…

Hong Kong Malaysian national Jonathan Chin culminated his 20+-year career at Boehringer Ingelheim and became GM of the firm’s Hong Kong and Macau affiliate in 2022. He explains his career path through multiple international roles, the shift arising from COVID-19 in Southeast Asia and China, as well as the characteristics of the…